Levetiracetam Hospira 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification
Decision 
Information 
1 issued on 
Issued2 / 
affected3  
IB/0038/G 
This was an application for a group of variations. 
05/07/2023 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
amended 
on 
SmPC, Annex 
II and PL 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
A.5.b - Administrative change - Change in the name 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
A.5.b - Administrative change - Change in the name 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
A.5.a - Administrative change - Change in the name 
and/or address of a manufacturer/importer 
responsible for batch release 
IA/0037/G 
This was an application for a group of variations. 
14/07/2022 
n/a 
B.II.d.2.a - Change in test procedure for the finished 
product - Minor changes to an approved test 
procedure 
B.II.d.2.a - Change in test procedure for the finished 
product - Minor changes to an approved test 
procedure 
IB/0036 
C.I.2.a - Change in the SPC, Labelling or PL of a 
14/06/2022 
generic/hybrid/biosimilar products following 
SmPC, 
Labelling and 
Page 2/11 
 
 
 
 
 
 
 
 
 
 
 
 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
N/0035 
Minor change in labelling or package leaflet not 
01/03/2022 
connected with the SPC (Art. 61.3 Notification) 
N/0033 
Minor change in labelling or package leaflet not 
01/10/2021 
connected with the SPC (Art. 61.3 Notification) 
IAIN/0034 
C.I.11.a - Introduction of, or change(s) to, the 
24/08/2021 
n/a 
obligations and conditions of a marketing 
authorisation, including the RMP - Implementation of 
wording agreed by the competent authority 
IB/0032/G 
This was an application for a group of variations. 
11/08/2021 
n/a 
PL 
PL 
PL 
B.II.d.2.a - Change in test procedure for the finished 
product - Minor changes to an approved test 
procedure 
B.II.b.3.a - Change in the manufacturing process of 
the finished or intermediate product - Minor change 
in the manufacturing process 
B.II.b.3.a - Change in the manufacturing process of 
the finished or intermediate product - Minor change 
in the manufacturing process 
B.II.b.3.a - Change in the manufacturing process of 
the finished or intermediate product - Minor change 
in the manufacturing process 
B.II.b.3.a - Change in the manufacturing process of 
Page 3/11 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
the finished or intermediate product - Minor change 
in the manufacturing process 
B.II.b.3.a - Change in the manufacturing process of 
the finished or intermediate product - Minor change 
in the manufacturing process 
B.II.b.4.a - Change in the batch size (including batch 
size ranges) of the finished product - Up to 10-fold 
compared to the originally approved batch size 
IB/0031/G 
This was an application for a group of variations. 
15/06/2021 
n/a 
B.I.b.1.z - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Other variation 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
B.III.1.a.2 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
IB/0030 
C.I.2.a - Change in the SPC, Labelling or PL of a 
02/06/2021 
09/07/2021 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IA/0029 
A.7 - Administrative change - Deletion of 
23/02/2021 
09/07/2021 
Annex II and 
manufacturing sites 
PL 
Page 4/11 
 
 
 
 
 
 
 
 
 
 
 
 
 
IB/0028/G 
This was an application for a group of variations. 
12/01/2021 
26/04/2021 
SmPC, 
Labelling and 
PL 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IB/0026 
C.I.z - Changes (Safety/Efficacy) of Human and 
11/11/2020 
26/04/2021 
SmPC, Annex 
Veterinary Medicinal Products - Other variation 
II and PL 
IA/0027 
A.7 - Administrative change - Deletion of 
20/10/2020 
n/a 
manufacturing sites 
IB/0025 
C.I.2.a - Change in the SPC, Labelling or PL of a 
18/02/2020 
26/04/2021 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
N/0024 
Minor change in labelling or package leaflet not 
02/12/2019 
26/04/2021 
PL 
connected with the SPC (Art. 61.3 Notification) 
Page 5/11 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IB/0023 
C.I.2.a - Change in the SPC, Labelling or PL of a 
12/09/2019 
18/12/2019 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
N/0022 
Minor change in labelling or package leaflet not 
09/04/2019 
18/12/2019 
PL 
connected with the SPC (Art. 61.3 Notification) 
IAIN/0021/G 
This was an application for a group of variations. 
11/01/2019 
18/12/2019 
Annex II and 
PL 
A.5.b - Administrative change - Change in the name 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
A.7 - Administrative change - Deletion of 
manufacturing sites 
B.II.b.2.c.1 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
T/0019 
Transfer of Marketing Authorisation 
25/09/2018 
22/11/2018 
SmPC, 
Labelling and 
PL 
R/0018 
Renewal of the marketing authorisation. 
20/09/2018 
20/11/2018 
SmPC, Annex 
Based on the review of data on quality, safety and efficacy, 
II, Labelling 
the CHMP considered that the benefit-risk balance of 
Levetiracetam Hospira in the approved indication remains 
Page 6/11 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
and PL 
favourable and therefore recommended the renewal of the 
marketing authorisation with unlimited validity. 
N/0020 
Minor change in labelling or package leaflet not 
24/10/2018 
18/12/2019 
PL 
connected with the SPC (Art. 61.3 Notification) 
N/0017 
Minor change in labelling or package leaflet not 
21/11/2017 
20/11/2018 
PL 
connected with the SPC (Art. 61.3 Notification) 
IA/0016/G 
This was an application for a group of variations. 
26/09/2017 
n/a 
B.I.b.1.c - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Addition of a new 
specification parameter to the specification with its 
corresponding test method 
B.III.1.a.2 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
N/0015 
Minor change in labelling or package leaflet not 
16/02/2017 
06/04/2017 
Labelling and 
connected with the SPC (Art. 61.3 Notification) 
PL 
II/0012 
Update of the section 4.4 and 4.8 of the SmPC to 
10/11/2016 
06/04/2017 
SmPC and PL 
In line with the changes agreed following the assessment of 
add warnings on acute kidney injury and on blood 
dyscrasias and to reflect rhabdomyolysis, blood 
creatine phosphokinase increased, acute kidney 
injury, encephalopathy as rare adverse drug 
reactions. The Package Leaflet was updated 
accordingly. These changes are in line with the 
PSUSA outcome for the originator product. 
the PSUSA for the reference product of Levetiracetam 
Hospira, section 4.4 of the SmPC is update to add that 
acute kidney injury has been associated very rarely with 
the use of levetiracetam. In addition, also cases of 
decreased blood cell count (neutropenia, agranulocytosis, 
leucopenia, thrombocytopenia and pancytopenia) have 
rarely been reported at the beginning of treatment and this 
Page 7/11 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
C.I.4 - Change(s) in the SPC, Labelling or PL due to 
new quality, preclinical, clinical or pharmacovigilance 
data 
is included in section 4.4 of the SmPC. 
The following rare adverse events have been added to 
section 4.8: rhabdomyolysis, blood creatine phosphokinase 
increased, acute kidney injury and encephalopathy. 
The Pl was updated accordingly. 
IAIN/0014/G 
This was an application for a group of variations. 
24/08/2016 
06/04/2017 
SmPC, Annex 
A.1 - Administrative change - Change in the name 
and/or address of the MAH 
B.II.b.2.c.1 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
II, Labelling 
and PL 
N/0013 
Minor change in labelling or package leaflet not 
17/06/2016 
06/04/2017 
PL 
connected with the SPC (Art. 61.3 Notification) 
IG/0693 
B.II.b.1.a - Replacement or addition of a 
02/06/2016 
n/a 
manufacturing site for the FP - Secondary packaging 
site 
IB/0010 
C.I.2.a - Change in the SPC, Labelling or PL of a 
08/04/2016 
06/04/2017 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IA/0009/G 
This was an application for a group of variations. 
18/03/2016 
n/a 
Page 8/11 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B.II.e.2.a - Change in the specification parameters 
and/or limits of the immediate packaging of the 
finished product - Tightening of specification limits 
B.II.e.2.b - Change in the specification parameters 
and/or limits of the immediate packaging of the 
finished product - Addition of a new specification 
parameter to the specification with its corresponding 
test method 
B.II.e.2.b - Change in the specification parameters 
and/or limits of the immediate packaging of the 
finished product - Addition of a new specification 
parameter to the specification with its corresponding 
test method 
B.III.1.a.2 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
IG/0645 
C.I.8.a - Introduction of or changes to a summary of 
17/12/2015 
n/a 
Pharmacovigilance system - Changes in QPPV 
(including contact details) and/or changes in the 
PSMF location 
IG/0555 
C.I.8.a - Introduction of or changes to a summary of 
22/05/2015 
n/a 
Pharmacovigilance system - Changes in QPPV 
(including contact details) and/or changes in the 
PSMF location 
IA/0005 
B.III.1.a.2 - Submission of a new/updated or 
04/09/2014 
n/a 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
Page 9/11 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
from an already approved manufacturer 
IG/0477 
C.I.8.a - Introduction of or changes to a summary of 
03/09/2014 
n/a 
Pharmacovigilance system - Changes in QPPV 
(including contact details) and/or changes in the 
PSMF location 
IA/0004/G 
This was an application for a group of variations. 
22/08/2014 
n/a 
B.II.e.2.a - Change in the specification parameters 
and/or limits of the immediate packaging of the 
finished product - Tightening of specification limits 
B.II.e.7.a - Change in supplier of packaging 
components or devices (when mentioned in the 
dossier) - Deletion of a supplier 
B.II.e.6.b - Change in any part of the (primary) 
packaging material not in contact with the finished 
product formulation - Change that does not affect 
the product information 
IAIN/0003 
B.III.1.a.1 - Submission of a new/updated or 
03/07/2014 
n/a 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - New certificate from 
an already approved manufacturer 
IAIN/0002 
C.I.8.a - Introduction of or changes to a summary of 
11/03/2014 
n/a 
Pharmacovigilance system - Changes in QPPV 
(including contact details) and/or changes in the 
PSMF location 
IB/0001 
C.I.2.a - Change in the SPC, Labelling or PL of a 
05/03/2014 
11/03/2015 
SmPC, 
Page 10/11 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
Labelling and 
PL 
Page 11/11 
 
 
 
 
 
 
 
